leadf
logo-loader
viewGlaxoSmithKline PLC

GlaxoSmithKline and Sanofi to supply EU with 300mln COVID-19 vaccine doses

A Phase 1/ 2 study is expected to start in September, followed by a Phase 3 study by the end of 2020

GlaxoSmithKline PLC -

GlaxoSmithKline PLC (LON:GSK) and Sanofi have said they had reached an advanced stage in discussions with the EU over the supply of 300mln doses of their COVID-19 vaccine currently under development.

Sanofi and GSK recently signed agreements with the United States for up to 100mln doses of the vaccine and to supply the UK with 60mln doses.  

The doses for the EU would be manufactured in European countries including France, Belgium, Germany and Italy, the drugs group's said in a joint statement.

"Today's announcement helps to ensure that millions of Europeans will have access to a potential vaccine protecting against COVID-19, once proven safe and effective," said Thomas Triomphe, executive vice president and global head of Sanofi Pasteur.

“It has been our steadfast commitment to provide a vaccine that is affordable and accessible to everyone, and we are grateful to the European Commission for their ongoing engagement and shared support of this effort," he added.

Sanofi is leading the clinical development and registration of the COVID-19 vaccine and expects a Phase 1/ 2 study to start in September, followed by a Phase 3 study by the end of 2020.

If data is positive, regulatory approval could be achieved by the first half of 2021, said the French company.

In parallel, Sanofi and GSK said they are scaling up manufacturing of the antigen (Sanofi) and adjuvant (Glaxo) to produce up to 1bn doses per year overall.

 

Quick facts: GlaxoSmithKline PLC

Price: 1493.4 GBX

LSE:GSK
Market: LSE
Market Cap: £74.93 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Litigation Capital Management reports 'tremendous growth in overall...

Litigation Capital Management Limited’s (LON:LIT) Patrick Moloney and Nick Rowles-Davies talk to Proactive London about their 'overall good results in a disruptive year'. Some of the operational highlights include the launch of the asset management division following close of US$150m Global...

7 hours, 36 minutes ago

2 min read